Head-to-head evidence
JR-131 vs rESP
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: Erythropoietin receptor (EPO-R) · full Chronic Kidney Disease pipeline
JR-131
Developed by Kissei Pharmaceutical
NCT02912494 · Phase 3 · completed
The study was double-blind and used an active darbepoetin alfa comparator, but the registry does not state whether participants were randomized or report the sample size. Its primary endpoint was change in hemoglobin, a surrogate measure. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
rESP
Developed by Shenyang Sunshine Pharmaceutical
NCT05211167 · Phase 3 · status unknown
This is a randomized, active-controlled Phase 3 trial with an adequately sized enrollment comparing the study drug against a standard recombinant erythropoietin, using change in hemoglobin, the measure that defines the anemia being treated, as its primary endpoint. However, the trial was not blinded, and results have not been posted yet. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: JR-131's landscape · rESP's landscape